GAGhadi Abdulmuin Althobaiti

Ghadi Abdulmuin Althobaiti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ghadi Abdulmuin Althobaiti has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy and safety of reproxalap for the treatment of dry eye disease: a systematic review and meta-analysis

    by Osama Almajhadi, Rana Alharthi, Ghadi Althobaiti, Elham Alharbi, Majed Al Qurashi

    Background: Reproxalap, a reactive aldehyde species inhibitor, has been proposed for dry eye disease (DED), but trial findings are inconsistent, and no quantitative synthesis exists. We assessed the efficacy and safety of reproxalap 0.25% ophthalmic solution versus vehicle in adults with DED. Methods: PubMed, Web of Science, ClinicalTrials.gov, gray literature, and manufacturer sources were searched through June 2025 (International Prospective Register of Systematic Reviews CRD420251069765; Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020). Two reviewers independently screened, extracted data, and assessed risk of bias. Random- or fixed-effects models were used according to heterogeneity. Standardized mean differences (SMDs), mean differences (MDs), and risk ratios (RRs) were pooled with 95% confidence intervals (CIs). Certainty was assessed using Grading of Recommendations, Assessment, Development, and Evaluations. Results: Eight randomized controlled trials (1,436 participants) were included. Reproxalap did not significantly improve ocular dryness (SMD, −0.07; 95% CI, −0.24 to 0.10; I² = 47%; p = 0.43) or conjunctival redness (MD, −0.06; 95% CI, −0.19 to 0.07; I² = 73%; p = 0.36; random-effects). Tear production significantly increased (MD, 2.20 mm; 95% CI, 1.45-2.94; I² = 0%; p < 0.0001). Adverse events (AEs) were more frequent with reproxalap (overall RR, 16.30; 95% CI, 4.46-59.55; I² = 94%; p < 0.0001), although the magnitude of excess varied by study setting: chamber trials showed a larger effect (RR, 25.98; 95% CI, 15.17-44.48; I² = 0%), while field trials showed a smaller but still elevated risk (RR, 6.01; 95% CI, 1.25-28.85). Certainty was moderate for AEs and tear production, and very low for dryness and redness. Conclusion: Reproxalap 0.25% significantly increased tear production by 2.2 mm, although its clinical relevance is uncertain given the ≥10 mm responder threshold. No benefit was observed for ocular dryness or conjunctival redness. Larger, well-designed field trials are needed to confirm clinical benefit.

  • Open Access

    Retinal Microvascular Biomarkers Measured by Optical Coherence Tomography Angiography in Neurodegenerative and Neurovascular Disorders: A Systematic Review and Meta-Analysis

    by Naif Alruwais, Ghadi Abdulmuin Althobaiti, Yazeed Bader Alaql, Sarah Abdullah H Almutairi, Wasan Mohammed Alshareef, Fai Anas Mahrous, Sarah Abdullah Saeed Aloqaybi, Razan Ali Awad Lasloom, Abdulrahman A Aljasser

    Purpose: Neurodegenerative and neurovascular disorders are increasingly recognized as major causes of disability worldwide and require accessible biomarkers for early detection and monitoring. Given the close anatomical and microvascular relationship between the retina and the central nervous system, optical coherence tomography angiography (OCTA) has emerged as a promising non-invasive technique for assessing retinal microvascular alterations associated with neurological disease. This systematic review and meta-analysis evaluated OCTA-derived retinal microvascular parameters as potential biomarkers of neurovascular dysfunction. Methods: This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines and registered in PROSPERO (CRD420261305354). PubMed, Embase, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials were searched from January 2015 to December 2025. Studies comparing OCTA-derived retinal vascular parameters between patients with neurodegenerative or neurovascular disorders and healthy controls were included. Primary outcomes were superficial capillary plexus vessel density (SCP-VD), deep capillary plexus vessel density (DCP-VD), and foveal avascular zone (FAZ) area. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using random-effects models. Results: Thirteen studies were included in the quantitative synthesis. Compared with healthy controls, patients with neurodegenerative or neurovascular disorders demonstrated significantly reduced SCP vessel density (SMD − 0.60, 95% CI − 0.78 to − 0.43; I2 = 43%) and DCP vessel density (SMD − 0.84, 95% CI − 1.15 to − 0.53; I2 = 78%). FAZ area was significantly enlarged in disease groups (SMD 0.62, 95% CI 0.29 to 0.94; I2 = 83%). Disease-specific subgroup analyses demonstrated generally consistent trends across the included disorders. Conclusion: OCTA-derived retinal microvascular alterations were consistently associated with neurodegenerative and neurovascular disorders. Reduced retinal vessel density, particularly within the deep capillary plexus, and enlargement of the FAZ may reflect underlying neurovascular dysfunction. While these findings support the potential role of OCTA as a non-invasive biomarker of neurological disease, the available evidence remains limited by methodological heterogeneity and predominantly observational study designs. Further longitudinal studies using standardized OCTA protocols are needed to establish the diagnostic and prognostic utility of these biomarkers.